Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
194
-
Total 13F shares, excl. options
-
49.7M
-
Shares change
-
-198K
-
Total reported value, excl. options
-
$481M
-
Value change
-
-$2.67M
-
Put/Call ratio
-
1.2
-
Number of buys
-
97
-
Number of sells
-
-65
-
Price
-
$9.68
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q2 2023
238 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q2 2023.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 194 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.7M shares
of 131M outstanding shares and own 38.01% of the company stock.
Largest 10 shareholders include BlackRock Inc. (8.33M shares), ARMISTICE CAPITAL, LLC (4.69M shares), NEA Management Company, LLC (3.97M shares), STATE STREET CORP (2.63M shares), GOLDMAN SACHS GROUP INC (1.74M shares), MORGAN STANLEY (1.69M shares), RENAISSANCE TECHNOLOGIES LLC (1.53M shares), GEODE CAPITAL MANAGEMENT, LLC (1.41M shares), VANGUARD GROUP INC (1.38M shares), and TWO SIGMA INVESTMENTS, LP (1.37M shares).
This table shows the top 194 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.